← back to search

Y. Gu

AbbVie (United States) · US

Area of research

Immunology · Rheumatology

Research interest

Research interests include Adalimumab, Medicine, Placebo, Clinical endpoint, and Psoriasis.

h-index

—

citations

99

works

1

NIH funding

—

primary concept

—

email

✉ Find email ↗

Recent publications

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Journal of the European Academy of Dermatology and Venereology 2016cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Y. Tu · The First Affiliated Hospital, Sun Yat-sen University1 papers (2016–2016)X.‐M. Liu · Dalian Medical University1 papers (2016–2016)Xing‐Hua Gao · Sun Yat-sen University Cancer Center1 papers (2016–2016)Hong Fang · Wenzhou Medical University1 papers (2016–2016)— · 1 papers (2016–2016)Liyan Xi · Sun Yat-sen University1 papers (2016–2016)Jiawen Chen · China Pharmaceutical University1 papers (2016–2016)Gang Wang · Wuhan Institute of Technology1 papers (2016–2016)Min Zheng · Sun Yat-sen University1 papers (2016–2016)Jie Zheng · Qingdao University1 papers (2016–2016)Fei Hao · Nanjing Agricultural University1 papers (2016–2016)— · 1 papers (2016–2016)Jie Gu · Dalian Medical University1 papers (2016–2016)— · 1 papers (2016–2016)Qing Sun · Guangzhou University of Chinese Medicine1 papers (2016–2016)Henrique D. Teixeira · AbbVie (United States)1 papers (2016–2016)Martin M. Okun · Twitter (United States)1 papers (2016–2016)Wei Lai · Sun Yat-sen University1 papers (2016–2016)Jianzhen Zhang · Ministry of Education of the People's Republic of China1 papers (2016–2016)